Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Trends in GLP-1 Receptor Agonist Prescribing Without Documented Indications
Diabetes, obesity & metabolism, 2026
Overweight and obesity induce Toll-like receptor 2-induced Type I IFN signaling
npj metabolic health and disease, 2026;4(1)
Peripheral nerve complications from medications utilised for weight loss: a systematic review
Journal of neurology, 2026;273(8)
Semaglutide-associated NAION: a proposed ‘two-hit’ model involving buried optic disc drusen and sustained hypohydration
The British journal of ophthalmology, 2026
Anti-Obesity Medications in Longevity and Aesthetic Medicine
Journal of clinical medicine, 2026;15(15)
Semaglutide and Liraglutide Modulate Oxidative Stress and Wound Repair in Normal Human Skin Cells Exposed to an In Vitro Diabetic-like Environment
International journal of molecular sciences, 2026;27(15)
Can Carica papaya Serve as an Adjunct to Semaglutide in Mitigating Diabetes-Induced Testicular Injury Through Modulation of Oxidative Stress, Inflammation, Apoptosis, and the miR-34c/miR-155-SIRT1/FOXO1 Axis? An Experimental and Chem-Bio-Informatics Study
International journal of molecular sciences, 2026;27(15)
GLP-1-based incretin therapy is associated with lower incident Alzheimer’s disease and cardiorenal events in adults with documented neuropsychiatric, cognitive, or sensory risk
Biology methods & protocols, 2026;11(1):bpag043
Discontinuation of Semaglutide Therapy for Obesity Management
JAMA network open, 2026;9(8):e2631371
Suspected Biphasic Anaphylaxis Following the First Known Dose of Tirzepatide: A Case Report and Brief Review of Reported Hypersensitivity Reactions
Cureus, 2026;18(8):e113910
Tirzepatide in recurrent hypertriglyceridemia-mediated pancreatitis and type 2 diabetes: a case report
Cardiovascular diabetology. Endocrinology reports, 2026;12(1)
Real-world evaluation of the effectiveness and safety of tirzepatide in patients with obesity: a prospective study
Clinical nutrition ESPEN, 2026;:105005
Semaglutide ameliorates traumatic sepsis-induced cardiac injury by activating the March5-ACSL4 axis to suppress ferroptosis
Free radical biology & medicine, 2026
Safety of glucagon-like peptide-1 receptor agonists in neuroendocrine neoplasms
European journal of endocrinology, 2026
MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice
Current hypertension reports, 2026;28(1)
Ability of Adults to Correctly Use Grey Market Peptide Semaglutide GLP-1 Receptor Agonists Acquired Without a Prescription
Public health reports (Washington, D.C. : 1974), 2026;:333549261464876
Atypical Anorexia Nervosa Developed in a Patient with Severe Obesity and Type 2 Diabetes Following Sleeve Gastrectomy and Postoperative Treatment with Semaglutide and Tirzepatide
Internal medicine (Tokyo, Japan), 2026
Structured Exercise During and After Incretin-Based Pharmacotherapy Discontinuation: A Narrative Review of Mechanisms, Evidence, and Prescription Guidance
Healthcare (Basel, Switzerland), 2026;14(15)
Incretin-Based Therapies Versus Bariatric and Metabolic Surgery for Obesity and Type 2 Diabetes Mellitus: A Head-to-Head Systematic Review of Glycaemic, Cardiovascular, Hepatic, Weight, and Quality-of-Life Outcomes
Cureus, 2026;18(8):e113777
Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era
Endocrinology, diabetes & metabolism;9(5):e70298